A References

Ball, N., M. T. Cronin, J. Shen, K. Blackburn, E. D. Booth, M. Bouhifd, E. Donley, L. Egnash, C. Hastings, D. R. Juberg, A. Kleensang, N. Kleinstreuer, E. D. Kroese, A. C. Lee, T. Luechtefeld, A. Maertens, S. Marty, J. M. Naciff, J. Palmer, D. Pamies, M. Penman, A. N. Richarz, D. P. Russo, S. B. Stuard, G. Patlewicz, B. van Ravenzwaay, S. Wu, H. Zhu, and T. Hartung. 2016. Toward Good Read-Across Practice (GRAP) guidance. ALTEX 33(2):149-166.

Belmonte, J. C. I., E. M. Callaway, P. Churchland, S. J. Caddick, G. Feng, G. E. Homanics, K.-F. Lee, D. A. Leopold, C. T. Miller, J. F. Mitchell, S. Mitalipov, A. R. Moutri, J. A. Movshon, H. Okano, J. H. Reynolds, D. Ringach, T. J. Sejnowski, A. C. Silva, P. L. Strick, J. Wu, and F. Zhang. 2015. Brains, genes and primates. Neuron 86(3):617-631.

Berry-Kravis, E., V. Des Portes, R. Hagerman, S. Jacquemont, P. Charles, J. Visootsak, M. Brinkman, K. Rerat, B. Koumaras, L. Zhu, G. M. Barth, T. Jaecklin, G. Apostol, and F. von Raison. 2016. Mavoglurant in Fragile X Syndrome: Results of two randomized, double-blind, placebo-controlled trials. Science Translational Medicine 8(321):321ra325.

Chang, S. M., S. L. Reynolds, N. Butowski, K. R. Lamborn, J. C. Buckner, R. S. Kaplan, and D. D. Bigner. 2005. GNOSIS: Guidelines for neuro-oncology: standards for investigational studies—reporting of phase 1 and phase 2 clinical trials. Neuro-Oncology 7(4):425-434.

Choi, D. W., R. Armitage, L. S. Brady, T. Coetzee, W. Fisher, S. Hyman, A. Pande, S. Paul, W. Potter, B. Roin, and T. Sherer. 2014. Medicines for the mind: Policy-based “pull” incentives for creating breakthrough CNS drugs. Neuron 84(3):554-563.

de Melo-Martin, I., D. Sondhi, and R. G. Crystal. 2012. Novel therapies, high-risk pediatric research, and the prospect of benefit: Learning from the ethical disagreements. Molecular Therapy 20(6):1095-1102.

Edens, B. M., S. Ajroud-Driss, L. Ma, and Y. C. Ma. 2015. Molecular mechanisms and animal models of spinal muscular atrophy. Biochimica et Biophysica Acta 1852(4):685-692.

Fejgin, K., J. Nielsen, M. R. Birknow, J. F. Bastlund, V. Nielsen, J. B. Lauridsen, H. Stefansson, S. Steinberg, H. B. Sorensen, T. E. Mortensen, P. H. Larsen, I. V. Klewe, S. V. Rasmussen, K. Stefansson, T. M. Werge, P. Kallunki, K. V. Christensen, and M. Didriksen. 2014. A mouse model that recapitulates cardinal features of the 15q13.3 microdeletion syndrome including schizophrenia- and epilepsy-related alterations. Biological Psychiatry 76(2):128-137.

Fellmann, C., B. G. Gowen, P-C. Lin, J. A. Doudna, and J. E. Corn. 2016. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nature Reviews Drug Discovery. http://www.nature.com/nrd/journal/vaop/ncurrent/abs/nrd.2016.238.html (accessed January 31, 2017). doi.10.1038/nrd.2016.238.

Finkbeiner, S., M. Frumkin, and P. D. Kassner. 2015. Cell-based screening: Extracting meaning from complex data. Neuron 86(1):160-174.

Fuji, R. N., M. Flagella, M. Baca, M. A. Baptista, J. Brodbeck, B. K. Chan, B. K. Fiske, L. Honigberg, A. M. Jubb, P. Katavolos, D. W. Lee, S. C. Lewin-Koh, T. Lin, X. Liu, S. Liu, J. P. Lyssikatos, J. O’Mahony, M. Reichelt, M. Roose-Girma, Z. Sheng, T. Sherer, A. Smith, M. Solon, Z. K. Sweeney, J. Tarrant, A. Urkowitz, S. Warming, M. Yaylaoglu, S. Zhang, H. Zhu, A. A. Estrada, and R. J. Watts. 2015. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Science Translational Medicine 7(273):273ra15.

Geerts, H., A. Spiros, P. Roberts, R. Twyman, L. Alphs, and A. A. Grace. 2012. Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response. PLoS One 7(12):e49732.

Goodkind, M., S. B. Eickhoff, D. J. Oathes, Y. Jiang, A. Chang, L. B. Jones-Hagata, B. N. Ortega, Y. V. Zaiko, E. L. Roach, M. S. Korgaonkar, S. M. Grieve, I. Galatzer-Levy, P. T. Fox, and A. Etkin. 2015. Identification of a common neurobiological substrate for mental illness. JAMA Psychiatry 72(4):305-315.

Haston, K. M., and S. Finkbeiner. 2016. Clinical trials in a dish: The potential of pluripotent stem cells to develop therapies for neurodegenerative diseases. Annual Review of Pharmacology and Toxicology 56:489-510.

Heidenreich, M., and F. Zhang. 2016. Applications of CRISPR–Cas systems in neuroscience. Nature Reviews Neuroscience 17:36-44.

Herzig, M. C., C. Kolly, E. Persohn, D. Theil, T. Schweizer, T. Hafner, C. Stemmelen, T. J. Troxler, P. Schmid, S. Danner, C. R. Schnell, M. Mueller, B. Kinzel, A. Grevot, F. Bolognani, M. Stirn, R. R. Kuhn, K. Kaupmann, P. H. van der Putten, G. Rovelli, and D. R. Shimshek. 2011. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Human Molecular Genetics 20(21):4209-4223.

IOM (Institute of Medicine). 2013. Improving the utility and translation of animal models for nervous system disorders: Workshop summary. Washington, DC: The National Academies Press.

IOM. 2014. Improving and accelerating therapeutic development for nervous system disorders: Workshop summary. Washington, DC: The National Academies Press.

Kaiser, T., and G. Feng. 2015. Modeling psychiatric disorders for developing effective treatments. Nature Medicine 21(9):979-988.

Kleensang, A., M. M. Vantangoli, S. Odwin-DaCosta, M. E. Andersen, K. Boekelheide, M. Bouhifd, A. J. Fornace, Jr., H. H. Li, C. B. Livi, S. Madnick, A. Maertens, M. Rosenberg, J. D. Yager, L. Zhaog, and T. Hartung. 2016. Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function. Scientific Reports 6:28994.

Lewis, D. A., A. A. Curley, J. R. Glausier, and D. W. Volk. 2012. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends in Neurosciences 35(1):57-67.

London, A. J., J. Kimmelman, and M. E. Emborg. 2010. Research ethics. Beyond access vs. protection in trials of innovative therapies. Science 328(5980):829-830.

Luechtefeld, T., A. Maertens, D. P. Russo, C. Rovida, H. Zhu, and T. Hartung. 2016. Global analysis of publicly available safety data for 9,801 substances registered under REACH from 2008-2014. ALTEX 33(2):95-109.

Nicholas, T., S. Duvvuri, C. Leurent, D. Raunig, T. Rapp, P. Iredale, C. Rowinski, R. Carr, P. Roberts, A. Spiros, and H. Geerts. 2013. Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial. Advances in Alzheimer’s Disease 2(3):83-93.

Paisan-Ruiz, C., S. Jain, E. W. Evans, W. P. Gilks, J. Simon, M. van der Brug, A. Lopez de Munain, S. Aparicio, A. M. Gil, N. Khan, J. Johnson, J. R. Martinez, D. Nicholl, I. M. Carrera, A. S. Pena, R. de Silva, A. Lees, J. F. Marti-Masso, J. Perez-Tur, N. W. Wood, and A. B. Singleton. 2004. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44(4):595-600.

Pamies, D., A. Bal-Price, A. Simeonov, D. Tagle, D. Allen, D. Gerhold, D. Yin, F. Pistollato, T. Inutsuka, K. Sullivan, G. Stacey, H. Salem, M. Leist, M. Daneshian, M. C. Vemuri, R. McFarland, S. Coecke, S. C. Fitzpatrick, U. Lakshmipathy, A. Mack, W. B. Wang, Y. Daiju, Y. Sekino, Y. Kanda, L. Smirnova, and T. Hartung. 2016. Good cell culture practice for stem cells and stem-cell-derived models. 2017. ALTEX 34(1):95-132.

PhRMA (Pharmaceutical Research and Manufacturers of America). 2010. Medicines in development for mental illnesses. http://phrma-docs.phrma.org/sites/default/files/pdf/mental_2010.pdf (accessed March 7, 2017).

PhRMA. 2014. Medicines in development for mental health 2014. http://phrma-docs.phrma.org/sites/default/files/pdf/2014-mental-health-report.pdf (accessed February 1, 2017).

Roberts, P., A. Spiros, and H. Geerts. 2016. A humanized clinically calibrated quantitative systems pharmacology model for hypokinetic motor symptoms in Parkinson’s disease. Frontiers in Pharmacology 7:6.

Samuel, G. O., S. Hoffmann, R. A. Wright, M. M. Lalu, G. Patlewicz, R. A. Becker, G. L. DeGeorge, D. Fergusson, T. Hartung, R. J. Lewis, and M. L. Stephens. 2016. Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: A scoping review. Environmental International 92-93:630-646.

Schizophrenia Working Group of the Psychiatric Genomics Consortium. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510):421-427.

Sena, E. S., H. B. van der Worp, P. M. Bath, D. W. Howells, and M. R. Macleod. 2010. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biology 8(3):e1000344.

Singh, T., M. I. Kurki, D. Curtis, S. M. Purcell, L. Crooks, J. McRae, J. Suvisaari, H. Chheda, D. Blackwood, G. Breen, O. Pietilainen, S. S. Gerety, M. Ayub, M. Blyth, T. Cole, D. Collier, E. L. Coomber, N. Craddock, M. J. Daly, J. Danesh, M. DiForti, A. Foster, N. B. Freimer, D. Geschwind, M. Johnstone, S. Joss, G. Kirov, J. Korkko, O. Kuismin, P. Holmans, C. M. Hultman, C. Iyegbe, J. Lonnqvist, M. Mannikko, S. A. McCarroll, P. McGuffin, A. M. McIntosh, A. McQuillin, J. S. Moilanen, C. Moore, R. M. Murray, R. Newbury-Ecob, W. Ouwehand, T. Paunio, E. Prigmore, E. Rees, D. Roberts, J. Sambrook, P. Sklar, D. St. Clair, J. Veijola, J. T. Walters, H. Williams, Swedish Schizophrenia Study, INTERVAL Study, DDD Study, UK10 K Consortium, P. F. Sullivan, M. E. Hurles, M. C. O’Donovan, A. Palotie, M. J. Owen, and J. C. Barrett. 2016. Rare loss-of-function variants in SETD1a are associated with schizophrenia and developmental disorders. Nature Neuroscience 19(4):571-577.

Stephens, M. L., K. Betts, N. B. Beck, V. Cogliano, K. Dickersin, S. Fitzpatrick, J. Freeman, G. Gray, T. Hartung, J. McPartland, A. A. Rooney, R. W. Scherer, D. Verloo, and S. Hoffmann. 2016. The emergence of systematic review in toxicology. Toxicological Sciences 152(1):10-16.

Steward, O., P. G. Popovich, W. D. Dietrich, and N. Kleitman. 2012. Replication and reproducibility in spinal cord injury research. Experimental Neurology 233(2):597-605.

TCSDD (Tufts Center for the Study of Drug Development). 2012. Pace of CNS drug development and FDA approvals lags other drug classes. Impact Report Volume 14, Number 2. Tufts University.

TCSDD. 2014. CNS drugs take longer to develop, have lower success rates, than other drugs. Impact Report Volume 16, Number 6. Tufts University.

Williams, J. Y., K. B. Fraser, N. N. Sukar, P. J. Webber, J. P. Lima Daher, M. S. Moehle, C. A. Stewart, R. M. Cowell, T. Dokland, T. Ye, D. Chen, T. A. Yacoubian, G. P. Siegal, R. A. Galemmo, D. J. Moore, D. G. Standaert, J. A. Mobley, and A. B. West. 2015. Leucine-rich repeat kinase 2 (LRRK2)

is secreted in urinary and CSF exosomes: Implication as a biomarker for Parkinson’s disease [abstract]. Movement Disorders 28(Suppl 1):1146.

Young, L., J. Sung, G. Stacey, and J. R. Masters. 2010. Detection of mycoplasma in cell cultures. Nature Protocols 5(5):929-934.

Zhou, Y., T. Kaiser, P. Monteiro, X. Zhang, M. S. Van der Goes, D. Wang, B. Barak, M. Zeng, C. Li, C. Lu, M. Wells, A. Amaya, S. Nguyen, M. Lewis, N. Sanjana, Y. Zhou, M. Zhang, F. Zhang, Z. Fu, and G. Feng. 2016. Mice with SHANK3 mutations associated with ASD and schizophrenia display both shared and distinct defects. Neuron 89(1):147-162.

Zimprich, A., S. Biskup, P. Leitner, P. Lichtner, M. Farrer, S. Lincoln, J. Kachergus, M. Hulihan, R. J. Uitti, D. B. Calne, A. J. Stoessl, R. F. Pfeiffer, N. Patenge, I. C. Carbajal, P. Vieregge, F. Asmus, B. Muller-Myhsok, D. W. Dickson, T. Meitinger, T. M. Strom, Z. K. Wszolek, and T. Gasser. 2004. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44(4):601-607.

This page intentionally left blank.